Goncalves Joana, CMO, reported a transaction classified as exercise at Oruka Therapeutics, Inc. involving 3500.000000 shares for an estimated $27300.00. Reported holdings after the transaction were 39718.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Medical Officer
These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.05 to $110.04, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.27 to $111.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.34 to $112.33, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.34 to $112.86, inclusive.
The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
0 other filings
0 recent txs